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AbstrACt 
Objective The aim of this study was to systematically 
evaluate the quality of the clinical practice guidelines 
(CPGs) for diabetes mellitus published in China over the 
period of January 2007 to April 2017.
Methods We searched the China National Knowledge 
Infrastructure, Chinese Biomedical Literature database, 
VIP database and WanFang databases and guideline 
websites for CPGs for diabetes mellitus published between 
January 2007 and April 2017 in China. Two reviewers 
independently screened the literature according to the 
inclusion and exclusion criteria and extracted data. We 
used the the Appraisal of Guidelines for Research and 
Evaluation II (AGREE II) tool (Canadian Institutes of Health 
Research, Ottawa, Canada) to evaluate the quality of the 
included guidelines, calculated the scores of each domain 
and evaluated the consistency among the assessors via 
use of the intragroup correlation coefficient. And then we 
compared the results with Chinese CPGs and international 
CPGs. We conducted a subgroup analysis based on 
different classification criteria and compared scores of 
each domain subgroup analyses.
results A total of 98 guidelines were identified. The 
correlation coefficient within the group was 0.93, 
suggesting that the consistency between the evaluators 
was good. The scores of the six domains of AGREE II 
were described in median (IQR) as follows: scope and 
purpose 53.7 (50.0–59.7), stakeholder involvement 31.5 
(27.3–37.0), rigour of development 19.1 (15.3–22.2), 
clarity of presentation 59.3 (50.0–64.8), applicability 18.1 
(13.9–25.7) and editorial independence 0.0 (0.0–0.0). The 
mean score in each domain of quality of Chinese diabetes 
CPGs was lower than that of CPGs published worldwide 
but higher than the mean score of Chinese guidelines of all 
topics. A funding source, the updated version, organisation 
and publishers of the guidelines and target fields are all 
the factors influencing the quality of CPGs to a certain 
degree.
Conclusions A large number of Chinese diabetes CPGs 
have been produced. Their quality remain unsatisfactorily 
low compared with CPGs worldwide, there is still room 
for improvement. Chinese guideline developers should 
pay more attention to the transparency of methodology, 
and use the AGREE II instrument to develop and report 
guidelines.
IntrOduCtIOn
Diabetes mellitus has become one of the 
leading causes of mortality and burden of 
disease worldwide, especially in China, which 
is now home to the largest number of diabetics 
worldwide.1 The prevalence of diabetes 
mellitus among adults in China has increased 
substantially in recent decades, rising from 
0.7% in 1980 to 10.9% in 2013.1–4 During the 
recent years, the government and organisa-
tions have started to pay more attention to this 
chronical disease, and national clinical prac-
tice guidelines (CPGs) for diabetes mellitus 
are also increasingly produced and dissemi-
nated. CPGs are defined as ‘statements that 
include recommendations intended to opti-
mise patient care, which are informed by a 
systematic review of evidence and an assess-
ment of the benefits and harms of alterna-
tive care options’.5 High-quality guidelines 
provide explicit recommendations for clin-
ical practice, helping to manage health condi-
tions and reduce the use of unnecessary, 
ineffective or harmful interventions.6 CPGs 
for diabetes mellitus have been developed to 
help optimise the management of the condi-
tion and improve the quality, appropriate-
ness and cost-effectiveness of patient care.7 
strengths and limitations of this study
 ► Covered all guidelines published on diabetes over 
the past one decade in China.
 ► It has the potential to contribute significantly in the 
upscaling guideline development
 ► Conducted a subgroup analysis based on different 
classification criteria and compared scores of each 
domain subgroup analyses.
 ► The AGREE II instrument only assesses the reporting 
of the different items and not the content validity of 
the recommendations.
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However, the potential of CPGs to improve patient care 
and resource use largely depends on the rigour of their 
development as well as the dissemination and implemen-
tation strategies.8 9 To the best of our knowledge, there has 
been no systematic evaluation of guidelines on diabetes 
mellitus in China. The growing number of guidelines 
may result in increasing variability and conflicts among 
guideline recommendations. China currently lacks 
capacity for evidence-based guideline development and 
coordination by a central agency. Most Chinese guide-
line users rely on recommendations developed by profes-
sional groups that lack demonstration of transparency 
(including conflicts of interest (COIs) management and 
evidence synthesis) and quality. In addition, mispercep-
tions about the role of guidelines in assisting practitioners 
as opposed to providing rules requiring adherence, and 
a perception that traditional Chinese medicine (TCM) 
cannot be appropriately incorporated in guidelines are 
present.10 Hence, we aimed to systematically review the 
existing Chinese guidelines for diabetes mellitus, assess 
their quality and eventually help Chinese guideline devel-
opers better follow methodological standards while devel-
oping guidelines in the future. However, the assessment 
of the content validity is not a part of this review as the 
instrument used in the review only assesses the reporting 
of the different items and not the clinical content. We will 
pay attention to the consistency of recommendations in 
different included guidelines loosely as well.
Identification of guidelines
We conducted a computerised search of four major 
academic databases: Chinese Biomedical Literature data-
base (http://www. sinomed. ac. cn/), WanFang database 
(Chinese Medicine Premier, http://www. wanfangdata. 
com. cn/), VIP (Chinese Journals Full-text database, 
http:// data. whlib. ac. cn/) and China National Knowl-
edge Infrastructure (http://www. cnki. net/). We used the 
same search strategy in all databases and restricted the 
search to guidelines published in China from January 
2007 through April 2017. The search strategy included 
Chinese translations of terms such as ‘guideline’ and 
‘diabetes mellitus’ (table 1). In addition, we searched 
guidelines for diabetes mellitus on several websites and 
search engines, including Google Scholar and Chinese 
Diabetes Mellitus Association (http://www. zhtnbxh. 
org/). If full text of guidelines could not be found, we 
contacted the author or the development agency. We 
also searched all articles published in Chinese Journal of 
Evidence-Based Medicine, Chinese Journal of Diabetes Mellitus 
and Chinese Journal of Diabetes before April 2017 manu-
ally. To identify guidelines published outside of indexed 
journals, our search of key databases was supplemented 
with a search of the grey literature. Grey literature were 
covered by systematically searching publications of all 
relevant diabetes societies and associations and other 
health organisations for CPGs that meet our inclusion 
criteria. We searched the PubMed specifically restricted 
to Chinese CPGs to retrieve the Chinese diabetes CPGs. 
Old or variant versions of guidelines where a new version 
was available, and guidelines not originally developed in 
China (such as Chinese versions of foreign CPGs, and 
adapted versions of CPGs from other countries), were 
excluded.
screening and data extraction
All studies were independently reviewed for eligibility by 
two researchers (LK, LL). Disagreements were resolved 
by face-to-face discussion, or in case of persistent disagree-
ment, by consultation with a third researcher (YG). We 
first screened the titles and abstracts, and in the next 
steps, the full texts of publications considered relevant. 
All included studies were imported in ENDNOTE. We 
first conducted one preliminary trial of data extraction. 
The extraction strategy was then discussed and agreed 
on by all researchers, and formal data collection was 
performed. Data extraction was done in Excel. For the 
validity and accuracy of data, the data collection was 
completed by two researchers independently. Disagree-
ments were resolved by discussion.
Evaluation of guidelines
AGREE II is an international, rigorously developed and 
validated instrument for evaluating CPGs.11 12 It consists 
of 23 key items organised within 6 domains. Each item in 
a domain is given a score from 1 (strongly disagree) to 7 
(strongly agree). The score for each domain is obtained 
by summing all the scores of the individual reviewers for 
all items in a domain and then standardising as follows: 
(obtained score−minimal possible score)/(maximal 
possible score−minimal possible score).13 All authors who 
were involved in assessing the guidelines using AGREE 
II had taken a formal training on the AGREE Enter-
prise website. We initially conducted two rounds of pilot 
appraisals with a total of 10 guidelines and discussed 
discrepancies, ensuring that all reviewers came to an 
agreement in understanding each item of AGREE II. Each 
guideline was independently evaluated by four reviewers.
Table 1 Search strategies
Search terms Explanation
#1* ‘zhinan’ or ‘zhiyin’ 
or ‘gongshi’ or 
‘caoan’
‘zhinan’,‘zhiyin’,‘gongshi’ and 
‘caoan’ mean ‘guideline’ in 
Chinese
#2 ‘tangniaobing’ or 
‘xiaokezheng’ or 
DM or NIDDM or 
IDDM or MODY or 
T2DM or T1DM
‘tangniaobing’ means diabetes 
mellitus in Chinese. ‘xiaokezheng’ 
is a term used by doctors of 
traditional Chinese medicine to 
refer to diabetes mellitus
#3 #1 and #2
*We used Zhinan as a subject heading in the Chinese Biomedical 
Literature database, and the terms ‘zhinan’,‘zhiyin’,‘gongshi’ 
and ‘caoan’ in the title of the paper in the other three full-text 
databases Wan Fang, VIP and China National Knowledge 
Infrastructure.
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Patient and public involvement
Patients were not involved in our study.
statistical analysis
We present the means and SD for AGREE II domain 
scores, and the number of cases and corresponding 
percentages for categorical variables. Data for each 
domain were analysed by Microsoft Excel 2013 and SPSS 
V.25.0. Intraclass correlation coefficients (ICCs) were 
used for testing inter-rater reliability among the four 
reviewers.14 We started the formal appraisal only after ICC 
reached at least 0.8 in the pilot appraisals. We confirmed 
whether data were in accordance with normal distribu-
tion at the beginning with SPSS V.25.0. If it was normally 
distributed, we would use one-way analysis of variance to 
compute the p value between the differences of multi-
groups. If it was not normally distributed, we descripted 
the data in median (IQR). And then we tested the statis-
tical significance of differences among several subgroups 
(≥2) using Kruskal-Wallis test. The independent sample 
t-test was used to compare the statistical significance of 
differences between two groups. All tests were two-sided, 
and p values <0.05 were considered to be statistically 
significant. Besides, we compared the scores of Chinese 
diabetes CPGs with those of Chinese CPGs15 and CPGs 
published worldwide16 of all topics.
rEsults
literature search
Our systematic search yielded 8065 records, of which 
3641 were excluded as duplicates. A total of 3979 records 
were excluded due to irrelevant topic after title and 
abstract screening, and 335 after reviewing full text. 
Twenty further guidelines were still excluded after eval-
uation. Eight guidelines were identified in the supple-
mentary website search, one guideline was retrieved by 
PubMed search and no guidelines in the manual searches 
of the three journals. Finally, 98 eligible guidelines were 
included in our analysis (figure 1).
Characteristics of the guidelines
The publication year of the included CPGs ranged 
between 2009 and 2017. The year with highest number 
of published diabetes CPGs (23) was 2011. Nine of the 
CPGs were updates of previous versions. The databases, 
exact terms and the time period of the search were accu-
rately described in five guidelines. Seventeen guidelines 
targeted type 2 diabetes mellitus, two guidelines type 1 
diabetes mellitus, two guidelines juvenile diabetes mellitus 
and one guideline latent autoimmune diabetes mellitus 
of adults. Some guidelines focused on complications 
only, including cardiovascular disease (five guidelines), 
diseases of the nervous system (five guidelines), kidney 
disease (five guidelines), hypertension (four guidelines), 
diabetic retinopathy (three guidelines) and diabetic foot 
(three guidelines). Seven guidelines reported that they 
received funding from governments, and two guidelines 
reported that they received funding from other academic 
organisations. Sixty guidelines were published in the 
Chinese Science Citation Database (CSCD), and one 
guideline online in Wiley Online Library ( wileyonlineli-
brary. com). Characteristics of the guidelines are displayed 
in online supplementary file 1.
AGrEE II results
The ICC for AGREE II assessment in the study was 0.929 
(95% CI 0.910 to 0.942). It indicates that appraisers 
reached an agreement about the items in AGREE II. 
The scores of the included guidelines are summarised 
in table 2. The data were not a normal distribution by 
analysing in the test of normality with SPSS, so the data 
were descripted in median (IQR). However, the differ-
ence of mean score and median score was subtle, mean 
score could be used to analyse to some extent. Subgroup 
analysis across domains has been done.
scope and purpose
The median score in this domain was 53.7 (50.0–59.7). 
The median score was the second highest among the 
domains. Most guidelines performed well in this domain, 
with no guidelines scoring below 25%.
stakeholder involvement
The median score for the overall score for this domain 
was 31.5 (27.3–37.0). Twenty-eight guidelines referred 
to methodologists or evidence-based experts in the 
Figure 1 Flow chart of the literature search of Chinese 
clinical practice guidelines (CPGs) for diabetes published 
between 2007 and 2017. CBM, Chinese Biomedical Literature 
database; CNKI, China National Knowledge Infrastructure.
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guideline development stage, and none involved patients 
in the development process. Only two CPGs scored at 
least 50%.
rigour of development
Two CPGs scored at least 50% in the domain ‘rigour of 
development’. The overall score in this domain was poor, 
with a median of 19.1 (15.3–22.2). Five CPGs described 
the systematic methods for searching and selecting 
evidence, 40 CPGs described the strengths and limitations 
of the body of evidence clearly, 29 CPGs used a nominal 
group technique or consensus-development conference, 
81 CPGs considered the health benefits, side effects and 
risks in formulating the recommendations, 91 CPGs indi-
cated a link between the supporting evidence and the 
recommendations and 4 CPGs were reviewed externally 
before publication. 9 guidelines were updated versions 
of older guidelines, but none of these described a proce-
dure for updating the guideline.
Clarity of presentation
Overall, the mean score for this domain was the highest 
among all domains, and only one guideline scored <25%. 
Recommendations were specific and unambiguous in all 
CPGs, although to various degrees. Four CPGs did not 
present the different options for management of the 
condition or health issue, and in one CPG key recom-
mendations were not identifiable.
Applicability
The median score for the overall quality score for this 
domain was 18.1 (13.9–25.7). 14 CPGs provided advice 
or tools on how the recommendations could be put into 
practice. Similarly, 14 CPGs described facilitators and 
barriers to its application. 14 CPGs considered the poten-
tial resource implications of applying the recommenda-
tions, and 87 CPGs presented monitoring or auditing 
criteria. 74 guidelines scored <25% for this domain.
Editorial independence
The scores for this domain were the lowest among all 
domains, with all 98 guidelines scoring <25%. Only one 
guideline reported that there were no COIs. 9 CPGs 
reported that they received funding from governments 
(seven guidelines) or academic organisations (two 
guidelines). However, these 9 guidelines failed to report 
whether the views of the funding body influenced the 
content of the guideline or not.
scores of AGrEE II in each domain based on different 
classification criteria
We conducted a subgroup analysis based on different clas-
sification criteria and compared scores of each domain 
subgroup analyses. Table 3 shows the domain scores and 
p values for different subgroups of the guidelines. It is 
evident from table 3 that CPGs of integrated TCM and 
Western medicine performed clearly better than CPGs on 
Western medicine or TCM in all domains. Guidelines that 
reported external funding scored better than guidelines 
that did not report funding in editorial independence. 
Guidelines that involved methodologists scored higher 
than guidelines not reporting methodologists and the 
differences were statistically significant in ‘stakeholder 
involvement’ and ‘rigour of development’. To some 
extent, reporting methodologists could increase the 
scores in ‘stakeholder involvement’ and ‘rigour of devel-
opment’. The difference between guidelines published in 
CSCD and non-CSCD journals was not statistically signif-
icant, developing organisation and type of guidelines as 
well. The results of the subgroup analysis showed that the 
updated version of the guidelines scored higher than the 
non-updated guidelines in all five fields (except for ‘field 
six: editorial independence’).
Comparison of AGrEE II scores between Chinese diabetes 
CPGs and CPGs published worldwide
Armstrong et al16 used the AGREE II tool to evaluate 
415 individual CPGs published between 1992 and 
2014. The results showed that the average scores of the 
guidelines in the six AGREE II domains were 75.8%, 
52.6%, 51.3%, 80.0%, 37.1% and 41.8%, respectively, 
as compared with the Chinese guidelines, which had a 
larger gap in all domains. Chen et al15 used the AGREE 
II tools to evaluate 269 CPGs in China in all fields, with 
the results of 64%, 52%, 48%, 81%, 43% and 26%, 
respectively. The scores of Chinese CPGs on diabetes 
were clearly higher than those of Chinese CPGs of all 
topics on average. The scores of Chinese diabetes CPGs 
were substantially lower than the international average 
of CPGs on all topics.
Table 2 AGREE II score of guidelines included
Domains Content
Median 
score (IQR, %)
Mean score 
(X±SD, %)
Score segmentation (number of guidelines (%))
<25% 25%~50% 50%~75% >75%
1 Scope and purpose 53.7 (50.0–59.7) 54.8±6.8 0 (0.0) 27 (27.6) 71 (72.4) 0 (0.0)
2 Stakeholder involvement 31.5 (27.3–37.0) 32.1±9.3 21 (21.5) 75 (76.5) 2 (2.0) 0 (0.0)
3 Rigour of development 19.1 (15.3–22.2) 20.2±10.8 81 (82.7) 15 (15.3) 2 (2.0) 0 (0.0)
4 Clarity of presentation 59.3 (50.0–64.8) 56.9±10.9 1 (1.0) 27 (27.6) 70 (71.4) 0 (0.0)
5 Applicability 18.1 (13.9–25.7) 19.2±8.7 74 (75.5) 24 (24.5) 0 (0.0) 0 (0.0)
6 Editorial independence 0.0 (0.0–0.0) 1.6±4.6 98 (100.0) 0 (0.0) 0 (0.0) 0 (0.0)
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Table 3 Scores of AGREE II based on different classification criteria
Subanalysis
Number of 
guidelines 
(%)
Domain scores (mean±SD, %)
Scope and 
purpose
Stakeholder 
involvement
Rigour of 
development
Clarity of 
presentation Applicability
Editorial 
independence
Developing organisation
  Chinese Medical Diabetes 
Association
60 (61.1%) 54.9±6.8 31.7±8.3 20.7±9.2 58.4±8.4 20.3±8.6 1.3±4.1
  Specially formed group* 18 (18.4%) 55.1±8.0 32.8±13.9 19.8±15.8 56.2±12.1 17.9±10.9 2.6±6.5
  National Health and Family 
Planning Commission
2 (2.1%) 45.4±9.2 27.8±2.6 13.5±17.2 41.7±32.7 13.9±0.0 0.0±0.0
  Ministry of Public Health 1 (1.0%) 44.4 16.7 4.2 29.6 0.0 0.0
  Hospitals 1 (1.0%) 59.3 31.5 21.5 59.3 16.7 0.0
  Collaboration of two or more 
organisations
14 (14.3%) 56.1±5.5 33.5±5.3 19.7±9.8 56.0±12.0 18.2±7.2 0.8±3.0
  Others 2 (2.1%) 52.8±3.9 39.8±11.8 25.0±7.9 53.7±10.5 18.8±6.9 8.3±11.8
  P value 0.36 0.54 0.77 0.18 0.48 0.35
Type of guidelines
  Diagnosis and treatment 27 (27.6) 55.8±7.9 30.3±6.3 18.6±6.6 59.2±7.9 22.3±9.5 1.6±4.8
  Treatment 22 (22.4%) 54.5±7.8 33.6±10.8 22.4±14.8 55.6±14.1 20.3±9.0 0.6±3.0
  Management 14 (14.3%) 53.4±6.0 31.0±6.3 18.3±6.9 56.1±10.3 14.9±5.3 1.2±4.5
  Prevention and treatment 9 (9.2%) 54.9±3.6 29.2±6.5 20.0±3.8 61.3±3.0 19.6±9.1 1.2±3.5
  Technology† 6 (6.1%) 51.2±2.2 38.9±6.6 18.6±6.9 53.4±10.0 16.7±4.6 2.8±6.8
  Medication‡ 5 (5.1%) 56.7±7.9 34.8±7.6 22.5±7.5 58.1±11.2 19.2±9.1 0.0±0.0
  Prevention 1 (1.0%) 68.5 37.0 24.3 64.8 29.2 0.0
  Healthcare 1 (1.0%) 59.3 14.8 7.6 40.7 15.3 0.0
  Comprehensive§ 13 (13.3%) 54.4±6.6 33.0±14.8 22.2±17.9 54.1±14.6 15.8±8.9 4.1±6.5
  P value 0.49 0.25 0.84 0.52 0.19 0.64
Publication year
  2009 3 (3.0%) 59.9±7.7 26.5±8.8 15.7±6.5 53.1±10.9 22.2±2.8 0.0±0.0
  2010 7 (7.1%) 52.1±8.1 28.8±6.2 14.7±4.3 50.8±10.8 13.5±11.9 2.4±6.3
  2011 23 (23.5%) 56.2±6.5 32.3±7.3 21.2±6.3 60.5±8.1 22.3±8.6 0.5±2.3
  2012 13 (13.3%) 53.3±6.2 34.5±12.9 23.5±17.6 54.6±11.6 16.0±7.2 3.2±6.2
  2013 10 (10.2%) 53.9±8.5 27.8±6.3 15.4±4.6 54.3±10.8 19.4±11.2 1.7±5.3
  2014 12 (12.2%) 56.8±7.8 32.7±8.4 19.6±5.3 60.6±6.8 22.7±9.7 1.4±4.8
  2015 9 (9.2%) 54.1±5.6 31.1±5.9 22.8±5.4 61.7±5.4 20.4±7.6 1.2±3.7
  2016 14 (14.3%) 53.0±6.1 32.1±7.5 18.6±9.5 53.2±15.1 16.1±2.9 0.8±3.0
  2017 7 (7.1%) 56.3±8.0 38.6±17.7 25.4±24.5 56.3±16.1 17.3±9.8 4.4±7.5
  P value 0.58 0.38 0.42 0.20 0.13 0.59
Western medicine or traditional Chinese medicine
  Western medicine 78 (79.6%) 53.7±6.7 31.2±7.3 18.9±7.3 56.5±11.9 18.2±8.3 1.3±4.4
  Traditional Chinese medicine 14 (14.3%) 58.6±5.9 31.1±7.5 19.9±4.8 58.7±5.6 21.8±9.7 1.6±4.0
  Integrated medicine 6 (6.1%) 59.3±7.9 44.4±22.1 36.9±31.5 60.8±1.4 24.3±8.5 4.6±7.2
  P value 0.01 0.002 0.001 0.53 0.11 0.23
Participation of methodologists in guideline development
  Methodologists involved 27 (27.6%) 55.6±7.2 36.9±11.4 25.2±16.8 58.3±10.0 19.8±6.6 1.4±4.2
  Not reported 71 (72.4%) 54.6±6.9 30.2±7.6 18.3±6.6 56.4±11.3 19.0±9.4 1.6±4.7
  P value 0.52 0.01 0.048 0.45 0.67 0.77
External funding
  No reported external funding 85 (86.7%) 55.2±6.6 32.3±8.3 19.7±9.6 56.6±11.4 19.7±8.3 0.5±2.6
  External funding reported 13 (13.3%) 52.6±8.7 30.6±14.4 23.2±17.0 58.8±6.8 15.9±10.7 8.8±7.5
Continued
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dIsCussIOn
Chinese diabetes CPGs have an advantage in quantity this 
decade
It is astonishing that almost 100 domestic guidelines of 
diabetes mellitus have been published in China in just 
mere one decade. We found that annual number of CPGs 
for diabetes mellitus published in domestic Chinese jour-
nals increased dramatically up to 2011, after which the 
number has remained fairly stable during the last few 
years.
The increasing number indicates that more and 
more Chinese diabetes CPGs are being applied to clin-
ical practice. Government agencies and the general and 
subspecialty medical societies in China promote the use 
of domestic guidelines in healthcare instead of merely 
adopting foreign guidelines, to account for the character-
istics and needs of Chinese patients and clinicians. Mean-
while, the number of published randomised controlled 
trials and systematic reviews in China is increasing quickly, 
which may be associated with rapid increase in burden of 
diabetics. This has laid the groundwork for development 
of guidelines.
Analysis of scores in each domain
An increasing amount of CPGs are being published. 
However, there is still much progress to be made as for 
quality of each domain. In the six major fields of the 
AGREE II tool scoring system, only the score of domain 
1, ‘scope and purpose’ and domain 4 ‘clarity of presen-
tation’ were >50%; as such, the scores of the other four 
fields need to be improved upon. The low score of 
domain 2, ‘stakeholder involvement’, was because most 
of the guidelines included in the present study did not 
take into account the multidisciplinary intersections of 
the participants, as well as the preferences and values of 
the target population. The low score of domain 3, ‘rigour 
of development’, means that generally those guidelines 
failed to show that they have conducted a systematic 
review on the best available evidences.17 The low score 
was possibly due to the fact that the reporting on the 
approach to its development lacked transparency. Several 
of included guidelines did not report the methods of the 
systematic literature search, forming their recommen-
dations and screening of evidence. Additionally, the low 
score of domain 5, ‘applicability’, suggested that most 
guidelines development agencies ignored the guidelines’ 
application, and that most guidelines did not provide 
relevant supporting documents or recommendations or 
emphasise the promotion and hindrance factors in the 
application process. In fact, failure to address the issue of 
implementation and to provide clear, practical advice can 
have important consequences. The low score of domain 
6, ‘editorial independence’, was likely due to the lack of 
disclosure of funding sources and related COIs. Only 
two of the included guidelines describes the methods by 
which potential COIs were sought and how COIs affected 
the recommendation development process. Failure to 
address the issue of implementation and to provide clear, 
practical advice can have important consequences. The 
Chinese diabetes guidelines’ score was lower than that of 
international DR guidelines in this field, indicating that 
the Chinese Guidance Group has not paid enough atten-
tion to the interests of the members of the disclosure 
group and to declaring clearly the views of the sponsors. 
If a COI is not declared, the recommendations may be 
affected by multiple interests and biased. It may not be 
that the quality of the guidelines themselves are low but 
rather the quality of the non-standard report of the guide-
lines.13 18 The low scores of these domains may be due to 
actual problems in guideline development, but because 
of the nature of the AGREE scoring, they may also simply 
be due to insufficient clarity and communication of the 
process used.19
Subanalysis
Number of 
guidelines 
(%)
Domain scores (mean±SD, %)
Scope and 
purpose
Stakeholder 
involvement
Rigour of 
development
Clarity of 
presentation Applicability
Editorial 
independence
  P value 0.19 0.54 0.25 0.31 0.13 0.001
Indexation in Chinese Sciences Citation Database (CSCD)
  Indexed in CSCD 60 (61.2%) 54.0±7.0 32.4±8.6 20.0±10.4 56.9±10.6 17.8±8.2 2.0±5.2
  Not indexed in CSCD 37 (37.8%) 56.1±6.8 32.0±10.0 20.8±11.5 57.4±11.4 21.5±9.2 1.0±3.4
  P value 0.14 0.65 0.82 0.98 0.46 0.27
Version
  Original 81 (82.7%) 54.8±7.3 31.9±9.3 19.9±11.5 56.2±0.1 18.9±0.1 1.9±5.0
  Updated 17 (17.3%) 55.0±4.8 32.9±9.2 21.4±6.6 60.2±9.4 20.7±6.9 0.0±0.0
  P value 0.14 0.43 0.38 0.30 0.20 0.00
*Groups specifically formed for developing the guideline; members were staff from different hospitals.
†Refers to guidelines about the use of medical equipment, eg, insulin injection needle.
‡Refers to guidelines about the use of specific drugs, eg, insulin.
§Refers to guidelines covering more than two types of guidelines.
Table 3 Continued
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Quality of Chinese diabetes CPGs were comparatively low
The mean score in each domain of the quality of Chinese 
diabetes CPGs was tremendously lower than that of CPGs 
published worldwide. The difference can be at least 
partly explained by the selection criteria: the review by 
Armstrong et al included guidelines that are indexed 
in Medline and therefore likely to be of high quality, 
whereas our study tried to find all guidelines on a specific 
topic in one country. Besides, there was a huge gap 
between the Chinese diabetes CPGs and CPGs published 
worldwide in the domain ‘editorial independence’: this 
domain was also the one that had lowest score overall. 
COIs are a significant issue worldwide, as can introduce 
bias into almost every step of the guideline develop-
ment process.20 Our results show that there are serious 
reporting flaws for potential COIs for the members of the 
guideline development groups in Chinese CPGs. Most 
foreign and international organisations, such as WHO, 
have their own COI disclosure policies for members 
of guideline panels,21 but until now, only few Chinese 
guideline-developing organisations have implemented 
such policies. Unlike in most other countries, in China 
the majority of guidelines are developed by professional 
committees, and despite reporting no external funding, 
many of these guidelines may be supported by pharma-
ceutical companies. It is critically important that guide-
line developers attend to declarations of potential COIs 
in a proactive, reasoned, transparent and defensible 
manner. An efficient way to decrease the influence of 
pharmaceutical companies could be to establish a govern-
ment-controlled public foundation to develop guidelines. 
Armstrong et al16 represented the quality of international 
CPGs, as compared with the Chinese guidelines, which 
had a larger gap in the ‘rigour of development’ and 
‘editorial independence’ domains. The wide variability 
observed in these scores is worrying, since these domains 
directly reflect the reliability of the guidelines. Some 
of the included guidelines did not report the specific 
process of development and a COI as well. Holmer et al22 
used the AGREE II tools to evaluate 24 CPGs in the field 
of blood glucose management of type 2 diabetes mellitus, 
ultimately gaining results of 64%, 52%, 48%, 81%, 43% 
and 26%, respectively. Included guidelines in our study 
covers all contexts involved with diabetes mellitus, while 
Holmer et al only focused on blood glucose management 
of type 2 diabetes mellitus. That might be the reason 
why scores of guidelines in study of Holmer et al behaved 
much better than the Chinese diabetes CPGs. Anwer et 
al23 selected seven evidence‐based CPGs for management 
of type 2 diabetes mellitus in adults after a series of group 
discussion meetings, and then required results of 89.7%, 
82.7%, 82.1%, 95.1%, 77.6% and 87.7%, respectively 
using the AGREE II tools. We can know that the quality of 
evidenced-based CPGs were much better to some extent. 
Chen et al15 used the AGREE II tools to evaluate 269 CPGs 
in China in all fields. These results suggested that the 
Chinese guidelines still had some problems in terms of 
participation and application, mainly because of lacked 
considerations about the participants in development of 
guidelines, and absence of the relevant report. There-
fore, guidelines makers subsequently should consider the 
participation of multidisciplinary personnel and provide 
some guidance in application. Besides, several studies 
revealed that there are considerable variations and even 
conflicting recommendations concerning type 2 diabetes 
mellitus management from different guidelines.24 25
Factors influencing the quality of CPGs
Many factors are capable of influencing the quality of 
CPGs. From the perspective of the funders, the quality 
of guidelines developed by organisations reporting a 
funding source was higher than those that did not report 
any funding. The scores of guidelines with methodolo-
gists taking part were higher than those not reporting 
methodologists. Evidence-based methods could improve 
the quality of CPGs, especially in stakeholder involve-
ment and rigour of development. The guideline devel-
opment groups involved methodological experts who 
could ensure that methodological checks were correctly 
applied and that the development process was fully docu-
mented.26 Developing guidelines based on the method-
ology of evidence-based medicine could improve the 
quality of CPGs.27 Yao et al28 conducted a study comparing 
the quality of TCM CPGs with non-TCM CPGs, and the 
result showed that the quality of TCM CPGs was much 
better. The quality of TCM CPGs was higher than that of 
CPGs for Western medicine, which was compliant with 
the results of the study of Yao et al. It means that tradi-
tional medicine has drawn a lot of attraction and the rele-
vant studies are becoming more scientific.
suggestions based on the results of the Chinese diabetes 
guidelines
First, evidence-based medicine emphasises focusing on the 
current optimal clinical medicine and clinicians’ skills, as 
well as taking patients’ preferences and values into consid-
eration. Guideline development based on the methodology 
of evidence-based medicine could improve the quality of 
CPGs. The development of guidelines should incorporate 
multidisciplinary experts. Second, the guidelines can be 
registered during their development and should follow the 
contents of these to increase their transparency. Third, the 
promotion and impediment factors should be described 
in detail during the guidelines application process, while 
supporting tools for how the recommendations are to be 
applied in practice should be offered. Fourth, the develop-
ment team members must also clearly state whether there 
are any potential COIs, and it is recommended that the 
editor of the medical journal ask the guidelines developers 
to provide a COI statement for all participating members 
as an attachment when delivering the guidelines.29 Fifth, a 
central agency in China directing the development of 
evidence-based guideline is definitely required and a 
call for more rigorous training of guideline developers 
in China is warranted. As well as the quality of evidence 
like meta-analyses and randomized controlled trial needs 
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to be improved.30 Sixth, a series of tools could be used to 
standardize the development of guidelines, such as that the 
guidelines report should follow the RIGHT report state-
ment in order to ensure the transparency of the guidelines. 
Grading of Recommendations Assessment, Develop-
ment and Evaluation curriculum vitae (GRADE CV) can 
help guideline developers assess a methodologist's exper-
tise with methods and tasks.31
strengths and limitations
Our review has several strengths. First, the systematic 
review of CPGs for diabetes mellitus quality attempted 
to cover all guidelines published on diabetes over the 
past one decade in China. Our structured and explicit 
approach increases the validity of the findings. Second, 
we used the AGREE II instrument, which is a scientific 
and valid tool to assess the quality of CPGs. Furthermore, 
we conducted two rounds (for a total of 10 guidelines) 
of pilot appraisals and resolved disagreements, which 
further enhanced the confidence in our results. The 
extensive search strategy covering both indexed and grey 
literature, use of multiple appraisers who will complete 
training and calibration to assess the quality of CPGs 
and application of the AGREE II instrument, which has 
established validity and reliability, are all strengths of this 
review and may help the delivery of better care.
This review has also limitations. Our study was 
restricted to English and Chinese language guidelines, 
which excluded a small number of additional guidelines. 
Furthermore, CPG developers did not report all the details 
in developing guidelines even if they included some of 
the items listed in AGREE in process. Therefore, the 
score of AGREE II may underestimate the methodolog-
ical quality of guidelines. Lastly, the AGREE II instrument 
only assesses the reporting of the different items and not 
the content validity of the recommendations. Currently, 
there is an ongoing research project, the AGREE‐REX: 
Recommendation Excellence project that aims at devel-
oping and validating a new tool that will complement the 
AGREE II by assessing the clinical credibility and imple-
mentation of CPGs.32 Current review covers the period 
from 2007 to 2017, however comparison was made, with 
2010 and 2012 publication data. Clinical guideline devel-
opment is a very dynamic process that progresses every 
year, so the comparison should just be a reference.
COnClusIOn
A large number of CPGs for diabetes mellitus have been 
produced in China. Generally speaking, the quality of 
Chinese diabetes CPGs remain unsatisfactorilyin compar-
ison with other guidelines according to the evaluation by 
the AGREE II instrument. However, there is still room for 
improvement, especially in the aspect of editorial inde-
pendence. Reporting the full texts of CPGs and COIss 
according to AGREE II checklists and abiding to the prin-
ciples of evidence-based medicine can further improve 
the quality of guidelines.
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